UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.65-77

2018

Volltextzugriff (PDF)

OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S001-S002

2021

Volltextzugriff (PDF)

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

The New England journal of medicine, 2016-11, Vol.375 (20), p.1946-1960

2016

Volltextzugriff (PDF)

P578 Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i706-i707

2023

Volltextzugriff (PDF)

P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i681-i682

2023

Volltextzugriff (PDF)

OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i55-i56

2023

Volltextzugriff (PDF)

P672 Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn’s disease studies, by population

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S450-S451

2018

Volltextzugriff (PDF)

P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i434-i435

2022

Volltextzugriff (PDF)

P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i564-i566

2023

Volltextzugriff (PDF)

OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study

Gut, 2017-07, Vol.66 (Suppl 2), p.A23

2017

Volltextzugriff (PDF)

DOP046 Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn's disease

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S54-S54

2017

Volltextzugriff (PDF)

A141 DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90MG Q8W IN PHASE III PROGRAM

Journal of the Canadian Association of Gastroenterology, 2018-03, Vol.1 (suppl_1), p.242-243

2018

Volltextzugriff (PDF)

Effector and memory CD8 + T cell fate coupled by T-bet and eomesodermin

Nature immunology, 2005-12, Vol.6 (12), p.1236-1244

2005

Volltextzugriff (PDF)

PWE-084 Whole Blood MRNA Expression Profiling of Crohn’S Disease in the Certifi Ustekinumab Study Discriminates Clinical Subtypes

Gut, 2013-06, Vol.62 (Suppl 1), p.A164-A164

2013

Volltextzugriff (PDF)

PWE-084Whole Blood MRNA Expression Profiling of Crohn'S Disease in the Certifi Ustekinumab Study Discriminates Clinical Subtypes

Gut, 2013-06, Vol.62 (Suppl 1), p.A164-A164

2013

Volltextzugriff (PDF)

P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i379-i380

2022

Volltextzugriff (PDF)

P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i460-i460

2022

Volltextzugriff (PDF)

AODWE-006 Efficacy of ustekinumab for induction and maintenance of histological healing in patient’s with crohn’s disease

Gut, 2017-07, Vol.66 (Suppl 2), p.A123

2017

Volltextzugriff (PDF)

P313 Steroid and opioid use among Crohn’s patients before and after initiation of ustekinumab

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S259-S259

2018

Volltextzugriff (PDF)

SAT0465 An integrated safety data analysis across all phase ii and phase iii clinical programs for ustekinumab in psoriatic arthritis, crohn's disease, and psoriasis

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.950

2017

Volltextzugriff (PDF)

P680 Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S459-S460

2019

Volltextzugriff (PDF)

OC-043 Long term efficacy and safety of ustekinumab for crohn’s disease: results from im-uniti long-term extension through 2 years

Gut, 2017-07, Vol.66 (Suppl 2), p.A22

2017

Volltextzugriff (PDF)

DOP052 Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein and biopsy gene expression analysis: results from Ustekinumab phase 3 studies

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S57-S58

2017

Volltextzugriff (PDF)

PTH-099Distinctive Gene Expression Profiles in the Whole Blood of Patients with Moderate to Severe Ulcerative Colitis and Crohn'S Disease

Gut, 2013-06, Vol.62 (Suppl 1), p.A251-A251

2013

Volltextzugriff (PDF)

PTH-099 Distinctive Gene Expression Profiles in the Whole Blood of Patients with Moderate to Severe Ulcerative Colitis and Crohn’S Disease

Gut, 2013-06, Vol.62 (Suppl 1), p.A251-A251

2013

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(77)

Sprache

Englisch
(77)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

11 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

P578 Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials

P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

P672 Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn’s disease studies, by population

P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis

P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial

OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study

DOP046 Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn's disease

A141 DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90MG Q8W IN PHASE III PROGRAM

Effector and memory CD8 + T cell fate coupled by T-bet and eomesodermin

PWE-084 Whole Blood MRNA Expression Profiling of Crohn’S Disease in the Certifi Ustekinumab Study Discriminates Clinical Subtypes

PWE-084Whole Blood MRNA Expression Profiling of Crohn'S Disease in the Certifi Ustekinumab Study Discriminates Clinical Subtypes

P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study

P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials

AODWE-006 Efficacy of ustekinumab for induction and maintenance of histological healing in patient’s with crohn’s disease

P313 Steroid and opioid use among Crohn’s patients before and after initiation of ustekinumab

SAT0465 An integrated safety data analysis across all phase ii and phase iii clinical programs for ustekinumab in psoriatic arthritis, crohn's disease, and psoriasis

P680 Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years

OC-043 Long term efficacy and safety of ustekinumab for crohn’s disease: results from im-uniti long-term extension through 2 years

DOP052 Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein and biopsy gene expression analysis: results from Ustekinumab phase 3 studies

PTH-099Distinctive Gene Expression Profiles in the Whole Blood of Patients with Moderate to Severe Ulcerative Colitis and Crohn'S Disease

PTH-099 Distinctive Gene Expression Profiles in the Whole Blood of Patients with Moderate to Severe Ulcerative Colitis and Crohn’S Disease

Suchergebnisse filtern